Microbot Medical Successfully Completed Integral Part Of The Verification And Validation Process
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical Inc. (MBOT) has announced the successful completion of the Electromagnetic Compatibility (EMC) testing, a part of the Verification and Validation (V&V) process for its LIBERTY Robotic Surgical System. This step is crucial for the Investigational Device Exemption (IDE) submission to the FDA, which is required to start clinical trials in the US. The company is committed to completing additional V&V testing soon, aiming to begin its first clinical trial.
November 13, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Microbot Medical Inc. has completed a key phase of the V&V process, moving closer to FDA clinical trials for its LIBERTY Robotic Surgical System.
The successful completion of the EMC testing is a positive development for Microbot Medical, indicating progress towards regulatory approval and clinical trials. This news is likely to be viewed favorably by investors, as it demonstrates the company's commitment to meeting high-quality and safety standards, which could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100